TP53 mutation profile in chronic lymphocytic leukemia: Evidence for a disease specific profile from a comprehensive analysis of 268 mutations

Leukemia

Volumn 24, Issue 12, 2010, Pages 2072-2079

  Zenz, T ^a   Vollmer, D ^a   Trbusek, M ^b   Smardova, J ^b   Benner, A ^c   Soussi, T ^d,e   Helfrich, H ^a   Heuberger, M ^a   Hoth, P ^a   Fuge, M ^a   Denzel, T ^a   Habe S ^a   Malcikova, J ^b   Kuglik, P ^b   Truong, S ^f   Patten, N ^f   Wu, L ^f   Oscier, D ^g   Ibbotson, R ^g   Gardiner, A ^g   Tracy, I ^g   Lin, K ^h   Pettitt, A ^h   Pospisilova, S ^b   Mayer, J ^b   Hallek, M ⁱ   Dohner H ^a   Stilgenbauer, S ^a   more..

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e SORBONNE UNIVERSITÉ   (France)

^f ROCHE MOLECULAR SYSTEMS   (United States)

^g ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

Author keywords

17p deletion; CLL; genetics; p53; TP53 mutation

Indexed keywords

PROTEIN P53;

ALLELE; ARTICLE; CARCINOGENESIS; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CODON; COMPARATIVE STUDY; CPG ISLAND; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; TRISOMY 12;

EID: 78650307334     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.208     Document Type: Article

References (38)

1. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem 2008; 77: 557-582.
2. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12: 303-312.
3. Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene 2007; 26: 2145-2156.
4. Zenz T, Kröber A, Scherer K, Habe S, Bühler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322-3329.
5. Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009; 23: 117-124.
6. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009; 15: 995-1004.
7. Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A et al. Detailed analysis of p53 pathway defects in fludarabine-refractory CLL: dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114: 2589-2597.
8. Malcikova J, Smardova J, Rocnova L, Tichy B, Kuglik P, Vranova V et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage. Blood 2009; 114: 5307-5314.
9. Trbusek M, Malcikova J, Smardova J, Kuhrova V, Mentzlova D, Francova H et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia 2006; 20: 1159-1161.
10. Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, Heuberger M et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009; 50: 510-513.
11. Bromidge T, Johnson S, Howe D. Spectrum of p53 mutations in low-grade B-cell malignancies. Leukemia 2008; 22: 1071-1073.
12. Newcomb EW. P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma 1995; 17: 211-221.
13. Newcomb EW, el Rouby S, Thomas A. A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies. Mol Carcinog 1995; 14: 227-232.
14. Prokocimer M, Unger R, Rennert HS, Rotter V, Rennert G. Pooled analysis of p53 mutations in hematological malignancies. Hum Mutat 1998; 12: 4-18.
15. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963-3967.
16. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
17. Smardova J, Nemajerova A, Trbusek M, Vagunda V, Kovarik J. Rare somatic p53 mutation identified in breast cancer: a case report. Tumour Biol 2001; 22: 59-66.
18. Smardova J, Pavlova S, Koukalova H. Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast. Pathol Oncol Res 2002; 8: 245-251.
19. Waridel F, Estreicher A, Bron L, Flaman JM, Fontolliet C, Monnier P et al. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 1997; 14: 163-169.
20. Malcikova J, Smardova J, Pekova S, Cejkova S, Kotaskova J, Tichy B et al. Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia. Mol Immunol 2008; 45: 1525-1529.
21. Morabito F, Filangeri M, Callea I, Sculli G, Callea V, Fracchiolla NS et al. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica 1997; 82: 16-20.
22. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T et al. The MDM2 oncogene overexpression in chronic lympho-cytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994; 84: 3158-3165.
23. Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008; 111: 1584-1593.
24. Soussi T, Rubio-Nevado JM, Ishioka C. MUT-TP53: a versatile matrix for TP53 mutation verification and publication. Hum Mutat 2006; 27: 1151-1154.
25. Soussi T, Asselain B, Hamroun D, Kato S, Ishioka C, Claustres M. et al. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 2006; 12: 62-69.
26. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998; 91: 4342-4349.
27. el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452-3459.
28. Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux P, Vanrumbeke M et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 1992; 6: 246-250.
29. Lepelley P, Preudhomme C, Vanrumbeke M, Quesnel B, Cosson A, Fenaux P. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia 1994; 8: 1342-1349.
30. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10: 477-484.
31. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervit I et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
32. Soussi T, Ishioka C, Claustres M, Beroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 2006; 6: 83-90.
33. Soussi T, Kato S, Levy PP, Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005; 25: 6-17.
34. Rodin SN, Rodin AS. Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells. Proc Natl Acad Sci USA 1998; 95: 11927-11932.
35. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-431.
36. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992; 4: 1-15.
37. Zenz T, Eichhorst BF, Busch R, Denzel T, Häbe S, Winkler D et al. TP53 mutation and survival in chronic lymphocytic leukaemia. JCO 2010, e-pub ahead of print 9 August 2010.
38. Stilgenbauer S, Zenz T, Winkler D, Buhler A, Busch R, Fingerle-Rowson G et al. Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 Trial. ASH Annu Meeting Abstr 2008; 112: 781.